Clinical trials: Dual Anti-Platelet Therapy
Stable Coronary Syndrome, Percutaneous Coronary Intervention
A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)
In patients with heart attacks, the current standard of care is to restore blood flow through percutaneous coronary intervention (PCI). This is done using stents (metal meshes) that opens up blockages.
- Conditions
- Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy, Ticagrelor
- Trial name
- NCT03224923
- Testing
- Ticagrelor 60mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Bleeding, Thrombosis
Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery
Research questions: 1. What is the absolute risk reduction for in-hospital major adverse cardiac events (MACE) associated with the use of dual anti-platelet therapy as compared with aspirin alone in this population? 2.
- Conditions
- Bleeding, Thrombosis, Cardiac Events
- Trial name
- OBTAIN (NCT01358422)
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 830 people
- Sponsor
- European Society of Anaesthesiology
Coronary Artery Disease
Short and Optimal Duration of Dual Antiplatelet Therapy Study
The purpose of this study is to evaluate safety of reduction of thienopyridine treatment period to 3 months after implantation of Cobalt-Chromium everolimus-eluting Stents.
- Trial name
- STOPDAPT (NCT01659034)
- Testing
- Thienopyridine for 3 months
- Where
- Japan
- Volunteers
- 1,525 people
- Sponsor
- Takeshi Morimoto
Acute Ischemic Stroke
Acute Ischemic Stroke Interventional Study
To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute ischemic stroke in addition to best emergency standard of care (including fibrinolysis by rtPA with or without added thrombectomy), with a…
- Trial name
- ACTIMIS (NCT03803007)
- Testing
- Intravenous ACT017 1000 mg
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Acticor Biotech
High Bleeding Risk, Coronary Artery Disease (CAD)
Drug-eluting Balloon Versus Drug-eluting Stent for High Bleeding Risk Angioplasty
Randomized, single-blind, single-center, non-inferiority clinical trial to compare target lesion failure (TLF) at 12 months in high bleeding risk patients undergoing elective coronary percutaneous intervention comparing…
- Conditions
- High Bleeding Risk, Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)
- Trial name
- DEBORA (NCT04885816)
- Testing
- Drug Eluting Balloon (DEB), Drug Eluting Stents (DES)
- Where
- Mexico
- Volunteers
- 5 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Acute Ischemic Stroke
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study.
- Trial name
- ACTISAVE (NCT05070260)
- Testing
- Intravenous glenzocimab (ACT017) 1000 mg
- Where
- 10 sites in United States, Germany
- Volunteers
- 438 people
- Sponsor
- Acticor Biotech
Coronary Artery Disease
Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
The DECREASE-PCI trial is a prospective, randomized, placebo controlled, double-blind, phase 4 study to evaluate efficacy and safety of triple anti-platelet therapy compared with dual antiplatelet therapy in patients treated with…
- Trial name
- NCT01346865
- Testing
- Cilostazol
- Where
- 12 sites in South Korea
- Volunteers
- 402 people
- Sponsor
- Seung-Jung Park